STOCK TITAN

Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Optimi Health (OTCQX: OPTHF) announced its 5mg naturally‑derived psilocybin capsules were selected for inclusion in Medibank’s psychotherapy program, an AUD $10M insurance‑backed initiative now expanded to reimburse psilocybin‑assisted therapy for treatment‑resistant depression (TRD).

Medibank serves ~4.2 million customers; program services will be delivered by Emyria’s Empax Centre in Perth and Optimi’s product will be supplied via its exclusive distributor, Mind Medicine Australia. Optimi’s capsules have been available in Australia since September 3, 2025. The program is part of a broader AUD $50M five‑year Medibank commitment to mental‑health innovation.

Optimi Health (OTCQX: OPTHF) ha annunciato che le sue capsule di psilocibina naturali da 5 mg sono state selezionate per l'inclusione nel programma di psicoterapia di Medibank, un'iniziativa sostenuta da assicurazione da AUD 10 milioni ora ampliata per rimborsare la psilocibina‑assistita terapia per la depressione resistente al trattamento (TRD). Medibank serve circa 4,2 milioni di clienti; i servizi del programma saranno forniti dal Empax Centre di Emyria a Perth e il prodotto di Optimi sarà fornito tramite il suo distributore esclusivo, Mind Medicine Australia. Le capsule di Optimi sono disponibili in Australia dal 3 settembre 2025. Il programma fa parte di un impegno più ampio di Medibank da AUD $50M in cinque anni per l'innovazione della salute mentale.
Optimi Health (OTCQX: OPTHF) anunció que sus cápsulas de psilocibina derivadas de forma natural de 5 mg fueron seleccionadas para incluirse en el programa de psicoterapia de Medibank, una iniciativa respaldada por un seguro de AUD 10 millones y ahora ampliada para reembolsar la terapia asistida con psilocybin para la depresión resistente al tratamiento (TRD). Medibank atiende a aproximadamente 4,2 millones de clientes; los servicios del programa serán proporcionados por el Empax Centre de Emyria en Perth y el producto de Optimi será suministrado a través de su distribuidor exclusivo, Mind Medicine Australia. Las cápsulas de Optimi están disponibles en Australia desde el 3 de septiembre de 2025. El programa forma parte de un compromiso más amplio de Medibank de AUD $50M durante cinco años para la innovación en salud mental.
옵티미 헬스(OTCQX: OPTHF)는 5mg의 자연 유래 psilocybin 캡슐이 메디뱅크의 심리치료 프로그램에 포함되도록 선정되었다고 발표했습니다. 이인은 보험으로 지원되는 AUD 10백만 달러 이니셔티브로, 이제 치료에 반응하지 않는 우울증(TRD)에 대한 psilocybin 보조 치료를 상환하도록 확대되었습니다. 메디뱅크는 약 420만 명의 고객을 제공합니다; 프로그램 서비스는 에이미리아의 엠팍스 센터(Perth)에서 제공되며 Optimi의 제품은 독점 유통사 Mind Medicine Australia를 통해 공급될 예정입니다. Optimi의 캡슐은 2025년 9월 3일부터 호주에서 구입 가능합니다. 이 프로그램은 정신건강 혁신에 대한 메디뱅크의 5년간 5천만 AUD 약속의 일부입니다.
Optimi Health (OTCQX: OPTHF) a annoncé que ses capsules de psilocybine dérivées naturellement de 5 mg ont été sélectionnées pour être incluses dans le programme de psychothérapie de Medibank, une initiative soutenue par une assurance d'AUD 10 millions et désormais élargie pour rembourser la thérapie assistée par psilocybine pour la dépression résistante au traitement (TRD). Medibank dessert environ 4,2 millions de clients ; les services du programme seront fournis par le Empax Centre d'Emyria à Perth et le produit d'Optimi sera fourni via son distributeur exclusif, Mind Medicine Australia. Les capsules d'Optimi sont disponibles en Australie depuis le 3 septembre 2025. Le programme fait partie d'un engagement plus large d'AUD 50 M sur cinq ans de Medibank en faveur de l'innovation en santé mentale.
Optimi Health (OTCQX: OPTHF) kündigte an, dass seine natürlich gewonnenen 5 mg Psilocybin-Kapseln in das Psychotherapie-Programm von Medibank aufgenommen wurden, eine von einer Versicherung unterstützte Initiative in Höhe von AUD 10 Mio., die nun erweitert wurde, um psilocybin‑unterstützte Therapien bei therapieresistenter Depression (TRD) zu erstatten. Medibank betreut ca. 4,2 Millionen Kunden; Programmleistungen werden vom Empax Centre von Emyria in Perth erbracht, und Optimis Produkt wird über seinen exklusiven Distributor Mind Medicine Australia geliefert. Optimis Kapseln sind in Australien seit dem 3. September 2025 erhältlich. Das Programm ist Teil eines umfassenderen AUD 50 Mio.-Fünfjahres-Engagements von Medibank für Innovationen im Bereich der psychischen Gesundheit.
أعلنت Optimi Health (OTCQX: OPTHF) أن كبسولات الـ psilocybin الطبيعية بجرعة 5 mg قد اختُيرت لإدراجها في برنامج العلاج النفسي التابع لـ Medibank، وهو مبادرة مدعومة بالتأمين بقيمة 10 ملايين دولار أسترالي وتوسّعت الآن لتغطية العلاج بمساعدة الـ psilocybin للاكتئاب المقاوم للعلاج (TRD). تخدم Medibank حوالي 4.2 مليون عميل؛ سيتم تقديم خدمات البرنامج من قبل مركز Empax التابع لـ Emyria في بيرث، وسيتم توريد منتج Optimi عبر موزعها الحصري Mind Medicine Australia. تتوفر كبسولات Optimi في أستراليا منذ 3 سبتمبر 2025. البرنامج جزء من التزام Medibank الأوسع بقيمة 50 مليون دولار أسترالي على مدى خمس سنوات بالابتكار في الصحة العقلية.
Optimi Health (OTCQX: OPTHF) 宣布其天然来源的5 mg 致幻蘑菇素胶囊被选入 Medibank 的心理治疗计划,这是一个由保险支持的1000万澳元计划,现在扩展为报销 psilocybin 辅助治疗以治疗难治性抑郁症(TRD)。Medibank 服务约420万名客户;该计划的服务将由 Emyria 的 Empax Centre 在珀斯提供,Optimi 的产品将通过其独家分销商 Mind Medicine Australia 供应。Optimi 的胶囊自 2025 年 9 月 3 日起在澳大利亚有售。该计划是 Medibank 在未来五年的五千万澳元精神健康创新承诺的一部分。
Positive
  • Selected for AUD $10M program covering psilocybin for TRD
  • Medibank reach: ~4.2 million customers
  • Commercial availability in Australia since September 3, 2025
  • Distribution via exclusive partner Mind Medicine Australia
  • Clinical delivery partner: Emyria’s Empax Centre in Perth
Negative
  • Coverage is limited to treatment‑resistant depression (TRD)
  • Program funding is AUD $10M, a subset of Medibank’s AUD $50M five‑year initiative

Australia's largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSD

Vancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion in Medibank's psychotherapy program, an AUD $10 million insurance-backed initiative that has now been expanded to cover Treatment-Resistant Depression ("TRD").

Medibank, Australia's largest private health insurer with approximately 4.2 million customers, has expanded its psychotherapy program to reimburse psilocybin-assisted therapy for patients with TRD, following its earlier funding of an MDMA-assisted therapy for Post-Traumatic Stress Disorder ("PTSD").

For this program, Emyria Limited, through its wholly owned Empax Centre located in Perth, Western Australia, is responsible for delivery of clinical services, and selected Optimi's psilocybin capsules for inclusion in the program through Optimi's exclusive distributor Mind Medicine Australia.

The Medibank psychotherapy program funding forms part of a broader AUD $50M initiative by the insurer, committed over five years to improving mental health access, innovation, and prevention — reinforcing its strategic shift to support novel therapies such as psilocybin and MDMA.

Optimi previously announced that its psilocybin capsules became available in Australia on September 3, 2025, under the Authorized Prescriber Scheme.

Dane Stevens, Chief Executive Officer of Optimi, said: "The inclusion of our psilocybin capsules in Medibank's insurance-backed program for treatment-resistant depression reflects the growing role of standardized psychedelic medicines in insured mental health care. This development helps ensure Medibank's patients will gain access to therapies that were previously out of financial reach and marks an important step towards Optimi's integration into insurance-backed regulated care."

How to Access Optimi's Capsules

To learn more about accessing Optimi's psilocybin or MDMA capsules, please contact sales@optimihealth.ca.

For Authorized Prescribers in Australia, please contact Mind Medicine Australia at medicines@mindmedicineaustralia.org.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us

About Optimi Health Corp.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi") is a Canadian Good Manufacturing Practices ("GMP") compliant, pharmaceutical drug manufacturer licensed by Health Canada for the handling of controlled substances and GMP production. From two 10,000-square-foot facilities in British Columbia and operating under a Drug Establishment License from Health Canada, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.com. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269191

FAQ

What did Optimi (OTCQX: OPTHF) announce on October 6, 2025 about psilocybin coverage?

Optimi said its 5mg psilocybin capsules were selected for Medibank’s AUD $10M psychotherapy program now covering TRD.

How many Medibank customers could potentially access Optimi psilocybin therapy?

Medibank serves about 4.2 million customers; the program is available to eligible members.

When did Optimi’s psilocybin capsules become available in Australia?

Optimi’s capsules have been available under the Authorized Prescriber Scheme since September 3, 2025.

Who will deliver the psilocybin‑assisted therapy under Medibank’s program?

Clinical services will be delivered by Emyria’s Empax Centre in Perth.

How will Optimi supply psilocybin to the Medibank program?

Optimi’s capsules will be supplied through its exclusive distributor, Mind Medicine Australia.

Is Medibank investing beyond the AUD $10M psychotherapy program?

Yes. The AUD $10M program is part of a broader AUD $50M five‑year commitment to mental‑health innovation.
Optimi Health

OTC:OPTHF

OPTHF Rankings

OPTHF Latest News

OPTHF Stock Data

19.11M
75.37M
21.54%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Princeton